[go: up one dir, main page]

AR092474A1 - Moduladores heterociclicos de los receptores de hormonas nucleares - Google Patents

Moduladores heterociclicos de los receptores de hormonas nucleares

Info

Publication number
AR092474A1
AR092474A1 ARP130103182A ARP130103182A AR092474A1 AR 092474 A1 AR092474 A1 AR 092474A1 AR P130103182 A ARP130103182 A AR P130103182A AR P130103182 A ARP130103182 A AR P130103182A AR 092474 A1 AR092474 A1 AR 092474A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
heteroaryl
ring
cycloalkyl
Prior art date
Application number
ARP130103182A
Other languages
English (en)
Inventor
Burchat Andrew
M Friedman Michael
D Gordon Thomas
C Ihle David
Y Lo Schiavo Gloria
D Mullen Kelly
Wang Lei
P Cusack Kevin
J Morytko Michael
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR092474A1 publication Critical patent/AR092474A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de fórmula (1) son útiles en el tratamiento de afecciones relacionadas con la inflamación. Los compuestos de la presente son de utilidad para el tratamiento de condiciones inmunológicas y oncológicas. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal farmacéuticamente aceptable, prodroga, metabolito biológicamente activo, isómero, o estereoisómero del mismo, donde: el Anillo A es un anillo heteroarilo o un anillo heterocíclico insaturado o parcialmente insaturado, donde: G es S, O, CR¹, C(R¹)₂, N, o NR¹; J es C, CR¹, C(R¹)₂, O, N, o NR¹; y, L es C, CR¹, C(R¹)₂, N, o NR¹; siempre que J no es O cuando G es O ó S; y, el Anillo A es una pirazina opcionalmente sustituida, piridina opcionalmente sustituida, o fenilo opcionalmente sustituido; el Anillo B es un anillo de siete miembros opcionalmente sustituido con deuterio, donde: X es -C(R⁵)₂-, -C(R⁵)=, -C(=O)-, N(Rᵃ), -S-, -S(O)-, o -S(O)₂-; o cuando X es -C(R⁵)₂-, ambos sustituyentes R⁵, junto con el átomo de carbono al cual se encuentran unidos, opcionalmente forman un anillo ciclopropilo espiro al Anillo B; Y es -C(R⁵)₂C(R⁵)₂-, =C(R⁵)C(R⁵)₂-, -C(R⁵)₂C(R⁵)=, =C(R⁵)C(R⁵)=, -N(Rᵃ)C(R⁵)₂-, -C(R⁵)₂N(Rᵃ)-, -C(=O)C(R⁵)₂-, -C(R⁵)₂C(=O)-, -O-C(=O)-, -C(=O)-O-, -OC(R⁵)₂-, o -C(R⁵)₂-O-; siempre que X-Y no forme enlaces -N(Rᵃ)-C(R⁵)₂-N(Rᵃ)-, S-C(R⁵)₂-N(Rᵃ)-, -S-C(R⁵)₂-O-, -O-C(R⁵)₂-N(Rᵃ)-, -C(=O)C(=O)-C(R⁵)₂-, -C(=O)-C(=O)-O-, -N(Rᵃ)-C(R⁵)₂-O-, -O-C(R⁵)₂-O-, -S-C(=O)C(R⁵)₂-, -S-C(=O)-O-, o -S-C(R⁵)₂-O-; y siempre que X-Y no resulte en un átomo de oxígeno adyacente a un átomo de nitrógeno, un átomo de azufre u otro átomo de oxígeno; y siempre que X-Y no resulte en dos átomos de hidrógeno adyacentes entre sí; el Anillo C es un anillo carbociclilo o heterociclilo saturado o parcialmente insaturado de cinco o seis miembros opcionalmente sustituido; R¹ es en forma independiente H, deuterio, -Br, -Cl, -F, -CF₃, -CN, -ORᵇ, alquilen C₁₋₃-Rᵇ opcionalmente sustituido, alquilo C₁₋₃ opcionalmente sustituido, arilo opcionalmente sustituido, cicloalquilo C₃₋₆ opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclo opcionalmente sustituido, -S(O)₂Rᵇ-, =O, o N(Rᵃ)(Rᵇ); R¹ᵃ es en forma independiente H, deuterio, -Br, -Cl, -F, -CF₃, -CN, alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₆ opcionalmente sustituido, heterociclo opcionalmente sustituido, S(O)₂-Rᵃ, o -N(Rᵃ)₂; R² es -CD₃, -CH₂CD₃, -CN, -alilo, -CH₂NHC(=O)alquilo C₁₋₃, -CH₂NHSO₂-alquilo C₁₋₃, -N(R)-SO₂-alquilo opcionalmente sustituido; -N(R)(Rᵍ), -N(R)-cicloalquilo opcionalmente sustituido, -N(R)-arilo opcionalmente sustituido, -N(R)-heteroarilo opcionalmente sustituido, -N(R)heterociclo opcionalmente sustituido, -N(R)C(O)-alquilo opcionalmente sustituido, -N(R)₂, C(O)N(Rᵃ)₂, -CH₂-arilo opcionalmente sustituido, -CH₂-cicloalquilo C₃₋₆ opcionalmente sustituido, alquilo C₁₋₃ opcionalmente sustituido, alquenilo C₂₋₃ opcionalmente sustituido, -CH₂-heteroarilo opcionalmente sustituido, -(CH₂)ₙ₁-heterociclo opcionalmente sustituido, -C(Rᵈ)₂-Rᵉ, o -C(=O)Rᵉ, siempre que cuando R² es -C(Rᵈ)₂-Rᵉ, sólo un Rᵈ puede ser OH; R³ es en forma independiente una unión, deuterio, -CD₃, -CF₃, -N(Rᵃ)SO₂Rᶜ, -N(Rᵃ)CORᶜ, -CON(Rᵃ)Rᶜ, -N(Rᵃ)COORᶜ, -N(Rᵃ)₂, -O-C(O)NR-alquilo opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, =O, -ORᵃ, -ORᶠ, alquilo C₁₋₄ opcionalmente sustituido, alquil C₁₋₄-O-alquilo C₁₋₄ opcionalmente sustituido, -(C(Rᵃ)²)ʳ-cicloalquilo C₃₋₆ sustituido, -(C(Rᵃ)₂)ʳ-arilo opcionalmente sustituido, -(C(Rᵃ)₂)ʳ-heteroarilo opcionalmente sustituido, -(C(Rᵃ)₂)ʳ-N(Rᵃ)-heteroarilo opcionalmente sustituido, -(C(Rᵃ)₂)ʳ-N(Rᵃ)-(C(Rᵃ)₂)ʳ-arilo opcionalmente sustituido, o una unidad espirocíclica carbocíclica o heterocíclica unida al anillo C; R⁴ es una unión, H, deuterio, -CD₃, -F, alquilo C₁₋₃ opcionalmente sustituido, -OH o -O-alquilo C₁₋₃ opcionalmente sustituido; R⁵ es en forma independiente H, deuterio, -CD₃, -F, -CF₃, -N(Rᵃ), -ORᵃ, o alquilo C₁₋₃ opcionalmente sustituido; y, Rᵃ es en forma independiente H, deuterio, cicloalquilo C₃₋₆ opcionalmente sustituido, o alquilo C₁₋₃ opcionalmente sustituido; Rᵇ es H, alquilo C₁₋₃ opcionalmente sustituido, arilo opcionalmente sustituido, cicloalquilo C₃₋₆ opcionalmente sustituido, heteroarilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; Rᶜ es alquilo C₁₋₃ opcionalmente sustituido o arilo opcionalmente sustituido; Rᵈ es en forma independiente H, deuterio, -OH, o alquilo C₁₋₆ opcionalmente sustituido; Rᵉ es -CF₃, arilo opcionalmente sustituido, alquilo C₁₋₆ opcionalmente sustituido, cicloalquilo C₃₋₆ opcionalmente sustituido, heteroarilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; Rᶠ es -H, -SO₂NH₂, -CH₂CO₂H, -CH₂CONH₂, -P(=O)(OH)(OH), -C(O)-alquilo C₁₋₆ opcionalmente sustituido, -C(O)N(alquilo C₁₋₆ opcionalmente sustituido)₂, -C(O)(alquilo C₁₋₆ opcionalmente sustituido)₂, -C(O)-arilo opcionalmente sustituido, -C(O)-heterociclo opcionalmente sustituido, -C(O)cicloalquilo C₃₋₆ opcionalmente sustituido, -C(O)-CR₂-heterociclo opcionalmente sustituido o -C(O)-CR₂-heteroarilo opcionalmente sustituido; Rᵍ es -CH₂-cicloalquilo C₃₋₆ opcionalmente sustituido, -CH₂-heteroarilo opcionalmente sustituido, o -CH₂-heterociclo opcionalmente sustituido; R es en forma independiente H o alquilo C₁₋₃; m es 0, 1 ó 2; n1 es en forma independiente 0 ó 1; p es 1, 2, 3 ó 4; y r es en forma independiente 0, 1 ó 2.
ARP130103182A 2012-09-07 2013-09-06 Moduladores heterociclicos de los receptores de hormonas nucleares AR092474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261698221P 2012-09-07 2012-09-07

Publications (1)

Publication Number Publication Date
AR092474A1 true AR092474A1 (es) 2015-04-22

Family

ID=50237618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103182A AR092474A1 (es) 2012-09-07 2013-09-06 Moduladores heterociclicos de los receptores de hormonas nucleares

Country Status (6)

Country Link
US (1) US9193744B2 (es)
EP (1) EP2892527A4 (es)
AR (1) AR092474A1 (es)
TW (1) TW201422590A (es)
UY (1) UY35014A (es)
WO (1) WO2014039757A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
TW202539687A (zh) * 2024-01-15 2025-10-16 香港商英矽智能科技知識產權有限公司 作為糖皮質激素受體調節劑的新化合物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111138A1 (en) 1993-01-15 1994-07-16 Thierry Godel Octahydrophenanthrene derivatives
NZ277373A (en) 1993-12-28 1998-07-28 Upjohn Co Iso(thio)chroman-1-ylethylpiperazine and -piperidine derivatives (analogues)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69940484D1 (de) 1998-04-06 2009-04-09 Astellas Pharma Inc Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie
HUP0103887A3 (en) 1998-10-07 2002-06-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor and pharmaceutical compositions containing such compounds
TR200103104T2 (tr) 1999-04-30 2002-05-21 Pfizer Products Inc. Glukortikoid alıcı modülatörleri
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
CN1468241A (zh) 2000-08-07 2004-01-14 作为gabaa受体配体的杂环化合物
IL146057A (en) 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
ES2262612T3 (es) 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
US7282591B2 (en) * 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
US20030224349A1 (en) 2002-05-31 2003-12-04 Pfizer Inc. Rapid assay to assess the potential for glucocorticoid analogs to promote the differentiation of human osteoblasts and predict bone safety
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
CA2499150A1 (en) * 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
ATE464296T1 (de) 2003-02-25 2010-04-15 Merck Sharp & Dohme Selektive nichtsteroidale glucocorticoid-rezeptor-modulatoren
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
AU2004289532A1 (en) 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
ES2446044T3 (es) * 2004-09-20 2014-03-06 Janssen Pharmaceutica Nv Derivados tetracíclicos novedosos que contienen heteroátomos útiles como moduladores de los receptores de hormonas sexuales esteroideas
US20060247266A1 (en) 2004-11-26 2006-11-02 Asahi Kasei Pharma Corporation Nitrogen-containing tricyclic compounds
WO2006081659A1 (en) 2005-02-01 2006-08-10 The University Of British Columbia Meroterpenoid inhibitors of phosphoinositide 3 kinase (pi3k)
US8093281B2 (en) 2005-04-14 2012-01-10 Glaxo Group Limited Indazoles as glucocorticoid receptor ligands
JP4873614B2 (ja) 2006-01-16 2012-02-08 国立大学法人 東京大学 カリウムチャネル開口薬
US8067447B2 (en) 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
DK2114888T3 (da) 2007-02-02 2011-01-24 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glu-cocorticoid-receptor-modulatorer
UA94639C2 (ru) 2007-02-02 2011-05-25 Пфайзер Продактс Інк. Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
EA201070535A1 (ru) 2007-11-30 2010-12-30 Пфайзер Лимитед Новые агонисты глюкокортикоидных рецепторов
JP2009209068A (ja) 2008-03-03 2009-09-17 Univ Of Tokyo カリウムチャネル開口薬
BRPI0915680A2 (pt) 2008-06-06 2019-09-24 Boehringer Ingelheim Int miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
MX2011001053A (es) 2008-07-28 2011-04-21 Pfizer Compuestos de fenantrenona, composiciones y metodos.
WO2010040527A1 (en) 2008-10-10 2010-04-15 Priaxon Ag Novel compounds which modulate kinase activity
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
CN102584860B (zh) 2011-01-17 2014-12-10 苏州大学 含吲哚结构的螺杂环化合物及其制备方法
TW201247610A (en) 2011-03-15 2012-12-01 Abbott Lab Nuclear hormone receptor modulators
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS

Also Published As

Publication number Publication date
WO2014039757A1 (en) 2014-03-13
TW201422590A (zh) 2014-06-16
UY35014A (es) 2014-03-31
EP2892527A4 (en) 2016-01-27
EP2892527A1 (en) 2015-07-15
US20140162985A1 (en) 2014-06-12
US9193744B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
ES2685568T3 (es) Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR088246A1 (es) Derivados de etinilo
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR085412A1 (es) Moduladores de los receptores de hormonas nucleares
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
ES2690355T3 (es) Tiazolopirimidinonas como moduladores de la actividad del receptor de NMDA
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR094797A1 (es) Derivados de pirrolotriazina como inhibidores de pi3k
AR092288A1 (es) Ligandos del receptor ep1
ES2568909T3 (es) Novedosos compuestos antagonistas del receptor de la neuroquinina 1
AR098522A1 (es) Compuesto de triazolo-piridina
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure